Results from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Treatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
The FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
A study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
Patients with diabetic macular edema (DME) treated with aflibercept Injection significantly improved vision and reduced the severity of diabetic retinopathy versus laser photocoagulation, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.